Southeast Asia's medical technology supply chain needs to be restructured to unlock growth potential — KPMG report analysis

The Supply Chain Concerns Behind the Growth Engine

Southeast Asia is becoming a high-growth market for global medtech companies. With a population base of over 700 million, continuously expanding government healthcare spending, and infrastructure upgrades, surgical volumes and diagnosis and treatment services are rising rapidly. Leading global medtech companies are targeting the region, anticipating double-digit growth and planning to deepen manufacturing and distribution footprints once key markets reach scale. However, a recent KPMG report warns that unless the "structural complexity" of regional supply chains is fundamentally reshaped, it will become a major constraint on growth in the short to medium term.

This assessment is not alarmist. The medtech supply chain in Southeast Asia faces two major structural challenges: internal complexity and external fragmentation.

Internal Complexity: SKU Proliferation and Capital Tie-Up

In multiple Southeast Asian markets, because government tender decisions and subsidy policies continue to drive demand for older product models, the number of stock keeping units (SKUs) at companies keeps rising. This directly leads to a surge in planning workload, higher safety stock levels, and increased working capital investment. For a region dominated by distribution models, multi-tiered channels further amplify this management difficulty. KPMG believes that without systematically optimizing the SKU portfolio and demand forecasting, corporate profit margins will be gradually eroded.

External Fragmentation: Inconsistent Regulations and Customs Process Differences

Although ASEAN has introduced frameworks such as the ASEAN Medical Device Directive (AMDD), member states still have significant differences in registration approval, quality standards, and localization requirements. The lack of harmonization in customs clearance processes further extends lead times and generates additional costs. This fragmentation makes it difficult for companies to deploy a unified and efficient supply chain network within the region, often forcing them to set up separate compliance pathways for different countries, resulting in duplicated resource investment.

Three Priority Actions: From Visibility to Selective Localization

KPMG recommends that medtech companies focus on three core areas for supply chain optimization:

1. End-to-End Visibility: This is the foundation for all improvements. Through demand sensing, control towers, integrated business planning (IBP), and direct access to consumption-level data such as hospital applications, digital ordering platforms, and connected devices, companies can gain real-time insight into inventory status and demand fluctuations, thereby improving responsiveness.

2. Strengthened Distributor Collaboration: Medtech distribution in Southeast Asia relies heavily on distributors. Companies should shift from loose transactional relationships to structured performance-based partnerships, with clear KPIs, governance mechanisms, continuous improvement processes, and compliance expectations. This not only reduces execution variability but also helps expand coverage to second- and third-tier cities.

3. Selective Localization: It is not recommended to replicate a full manufacturing base in every country. Companies should only localize where needed for tenders, local content requirements, or specific regulatory needs. Localization without a clear scope can lead to process duplication, fragmented compliance pathways, and increased management costs.

Regional Harmonization: Collective Action Is ImperativeKPMG emphasizes that isolated changes at the enterprise level alone cannot fully offset the costs and delays caused by regulatory fragmentation and uncoordinated customs procedures. The existing ASEAN Mutual Recognition Arrangements on Medical Devices (AMDD) and the Regional Comprehensive Economic Partnership (RCEP) provide a policy foundation, but without closer regional cooperation, these mechanisms may remain conceptual. Achieving true regulatory reliance, document standardization, and reduction of duplicate audits requires joint efforts from member state governments and industries.

Long-Term Outlook: Can Southeast Asia Become a Hub for the Medical Technology Supply Chain?

Southeast Asia possesses the fundamental elements for becoming a resilient medical technology supply chain hub: robust demand, continuously improving policy frameworks, and steadily enhancing operational capabilities. However, the winners will be those who specifically design their supply chains to address the region's characteristic of "fragmented regulation coexisting with shared demand." This process is not only about enterprise transformation but will also drive deeper integration of the ASEAN Economic Community in the healthcare sector.

As regional healthcare upgrades accelerate and population aging intensifies, the strategic importance of the Southeast Asian medical technology market will continue to rise. Supply chain restructuring is not optional; it is the necessary path to sustainable growth.